[The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer].
OBJECTIVE
To investigate the predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer.


METHODS
Forty-two patients with advanced ovarian cancer underwent complete resection plus platinum/paclitaxel as first-line adjuvant chemotherapy. The clinical outcomes were observed. Immunohistochemistry was used to detect the expression of p53, a tumor suppressor protein, and P-glycoprotein (Pgp), a multi-drug resistance associated gene product, in the specimens resected from operation. Retrospectively analysis of 42 cases r patients with. To calculate the complete response (CR) rate and early recurrence (ER) rate and to observe. The relationship between the parameters about clinical outcomes and some clinico-pathological variables, such as age, pathological type, differentiation degree, residual tumor, and molecular markers p53 and Pgp, was analyzed.


RESULTS
Twenty-four patients (57%) showed CR and 7 (13%) showed ER. The CR rate of the p53 positive patients was 74%, higher than that of the p53 negative patients (44%, P = 0.065). The ER rate of the patients with residual tumor less than 2 cm was 4%, significantly lower than those with residual tumor > or = 2 cm (P = 0.018). Logistic regression analysis indicated that Pgp positivity and residual tumor > or = 2 cm were independent risk factors of ER.


CONCLUSIONS
Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer. The p53 positive patients are more sensitive to this protocol, and the Pgp positive patients and the patients with residual tumor > or = 2 cm are more resistant to this protocol.
Wei
Feng-hua
FH
Department of Obstetrics and Gynecology, Beijing Hospital, Beijing 100730, China.
Zhao
Xiao-dong
XD
Zhang
Yi
Y
He
Shu-rong
SR
Yang
Li
L
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010053:Ovary / Q000187:drug effects / Q000378:metabolism / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D010984:Platinum / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D016159:Tumor Suppressor Protein p53; D010984:Platinum; D017239:Paclitaxel